|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PARP1 |
Gene summary for PARP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PARP1 | Gene ID | 142 |
| Gene name | poly(ADP-ribose) polymerase 1 | |
| Gene Alias | ADPRT | |
| Cytomap | 1q42.12 | |
| Gene Type | protein-coding | GO ID | GO:0000002 | UniProtAcc | A0A024R3T8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 142 | PARP1 | GSM4909281 | Human | Breast | IDC | 7.32e-18 | 4.57e-01 | 0.21 |
| 142 | PARP1 | GSM4909282 | Human | Breast | IDC | 8.79e-04 | 2.75e-01 | -0.0288 |
| 142 | PARP1 | GSM4909285 | Human | Breast | IDC | 1.48e-37 | 6.11e-01 | 0.21 |
| 142 | PARP1 | GSM4909286 | Human | Breast | IDC | 6.97e-13 | 3.28e-01 | 0.1081 |
| 142 | PARP1 | GSM4909287 | Human | Breast | IDC | 1.27e-04 | 3.52e-01 | 0.2057 |
| 142 | PARP1 | GSM4909290 | Human | Breast | IDC | 3.16e-04 | 3.44e-01 | 0.2096 |
| 142 | PARP1 | GSM4909293 | Human | Breast | IDC | 2.71e-40 | 6.55e-01 | 0.1581 |
| 142 | PARP1 | GSM4909298 | Human | Breast | IDC | 3.17e-08 | 2.63e-01 | 0.1551 |
| 142 | PARP1 | GSM4909301 | Human | Breast | IDC | 1.67e-02 | 2.40e-01 | 0.1577 |
| 142 | PARP1 | GSM4909306 | Human | Breast | IDC | 5.53e-14 | 3.82e-01 | 0.1564 |
| 142 | PARP1 | GSM4909307 | Human | Breast | IDC | 3.77e-15 | 4.99e-01 | 0.1569 |
| 142 | PARP1 | GSM4909308 | Human | Breast | IDC | 4.28e-25 | 6.54e-01 | 0.158 |
| 142 | PARP1 | GSM4909311 | Human | Breast | IDC | 4.76e-07 | -8.56e-02 | 0.1534 |
| 142 | PARP1 | GSM4909317 | Human | Breast | IDC | 2.37e-02 | 2.31e-01 | 0.1355 |
| 142 | PARP1 | GSM4909319 | Human | Breast | IDC | 1.39e-26 | 1.94e-01 | 0.1563 |
| 142 | PARP1 | brca2 | Human | Breast | Precancer | 2.79e-08 | 2.01e-01 | -0.024 |
| 142 | PARP1 | brca3 | Human | Breast | Precancer | 6.18e-04 | 2.33e-01 | -0.0263 |
| 142 | PARP1 | M2 | Human | Breast | IDC | 3.08e-11 | 7.43e-01 | 0.21 |
| 142 | PARP1 | NCCBC14 | Human | Breast | DCIS | 4.43e-22 | 7.15e-01 | 0.2021 |
| 142 | PARP1 | NCCBC3 | Human | Breast | DCIS | 4.66e-03 | 2.62e-01 | 0.1198 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00460349 | Breast | Precancer | ATP metabolic process | 82/1080 | 277/18723 | 1.94e-36 | 5.19e-33 | 82 |
| GO:00971939 | Breast | Precancer | intrinsic apoptotic signaling pathway | 59/1080 | 288/18723 | 8.07e-18 | 3.60e-15 | 59 |
| GO:20012339 | Breast | Precancer | regulation of apoptotic signaling pathway | 65/1080 | 356/18723 | 7.70e-17 | 3.17e-14 | 65 |
| GO:20012429 | Breast | Precancer | regulation of intrinsic apoptotic signaling pathway | 41/1080 | 164/18723 | 6.48e-16 | 2.31e-13 | 41 |
| GO:00069799 | Breast | Precancer | response to oxidative stress | 70/1080 | 446/18723 | 1.59e-14 | 4.26e-12 | 70 |
| GO:00067547 | Breast | Precancer | ATP biosynthetic process | 21/1080 | 57/18723 | 2.31e-12 | 4.26e-10 | 21 |
| GO:00092067 | Breast | Precancer | purine ribonucleoside triphosphate biosynthetic process | 22/1080 | 68/18723 | 1.41e-11 | 1.88e-09 | 22 |
| GO:00091457 | Breast | Precancer | purine nucleoside triphosphate biosynthetic process | 22/1080 | 69/18723 | 1.95e-11 | 2.43e-09 | 22 |
| GO:00485459 | Breast | Precancer | response to steroid hormone | 53/1080 | 339/18723 | 3.07e-11 | 3.66e-09 | 53 |
| GO:00092017 | Breast | Precancer | ribonucleoside triphosphate biosynthetic process | 22/1080 | 74/18723 | 9.18e-11 | 1.00e-08 | 22 |
| GO:00091448 | Breast | Precancer | purine nucleoside triphosphate metabolic process | 24/1080 | 88/18723 | 9.66e-11 | 1.03e-08 | 24 |
| GO:00092057 | Breast | Precancer | purine ribonucleoside triphosphate metabolic process | 23/1080 | 82/18723 | 1.27e-10 | 1.34e-08 | 23 |
| GO:00621979 | Breast | Precancer | cellular response to chemical stress | 51/1080 | 337/18723 | 2.40e-10 | 2.34e-08 | 51 |
| GO:00091427 | Breast | Precancer | nucleoside triphosphate biosynthetic process | 23/1080 | 85/18723 | 2.82e-10 | 2.69e-08 | 23 |
| GO:00091997 | Breast | Precancer | ribonucleoside triphosphate metabolic process | 23/1080 | 89/18723 | 7.65e-10 | 6.66e-08 | 23 |
| GO:00091418 | Breast | Precancer | nucleoside triphosphate metabolic process | 26/1080 | 112/18723 | 7.72e-10 | 6.66e-08 | 26 |
| GO:00709979 | Breast | Precancer | neuron death | 50/1080 | 361/18723 | 7.75e-09 | 5.70e-07 | 50 |
| GO:00319608 | Breast | Precancer | response to corticosteroid | 30/1080 | 167/18723 | 2.50e-08 | 1.65e-06 | 30 |
| GO:00514029 | Breast | Precancer | neuron apoptotic process | 38/1080 | 246/18723 | 2.68e-08 | 1.75e-06 | 38 |
| GO:00345999 | Breast | Precancer | cellular response to oxidative stress | 42/1080 | 288/18723 | 2.78e-08 | 1.79e-06 | 42 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0541518 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
| hsa042108 | Breast | Precancer | Apoptosis | 25/684 | 136/8465 | 7.61e-05 | 6.87e-04 | 5.26e-04 | 25 |
| hsa0541519 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
| hsa0421013 | Breast | Precancer | Apoptosis | 25/684 | 136/8465 | 7.61e-05 | 6.87e-04 | 5.26e-04 | 25 |
| hsa0541523 | Breast | IDC | Diabetic cardiomyopathy | 67/867 | 203/8465 | 3.17e-19 | 8.59e-18 | 6.43e-18 | 67 |
| hsa0421022 | Breast | IDC | Apoptosis | 31/867 | 136/8465 | 1.34e-05 | 1.61e-04 | 1.20e-04 | 31 |
| hsa0541533 | Breast | IDC | Diabetic cardiomyopathy | 67/867 | 203/8465 | 3.17e-19 | 8.59e-18 | 6.43e-18 | 67 |
| hsa0421032 | Breast | IDC | Apoptosis | 31/867 | 136/8465 | 1.34e-05 | 1.61e-04 | 1.20e-04 | 31 |
| hsa0541543 | Breast | DCIS | Diabetic cardiomyopathy | 65/846 | 203/8465 | 1.81e-18 | 4.87e-17 | 3.59e-17 | 65 |
| hsa0421041 | Breast | DCIS | Apoptosis | 29/846 | 136/8465 | 5.92e-05 | 5.97e-04 | 4.40e-04 | 29 |
| hsa0541553 | Breast | DCIS | Diabetic cardiomyopathy | 65/846 | 203/8465 | 1.81e-18 | 4.87e-17 | 3.59e-17 | 65 |
| hsa0421051 | Breast | DCIS | Apoptosis | 29/846 | 136/8465 | 5.92e-05 | 5.97e-04 | 4.40e-04 | 29 |
| hsa05415 | Colorectum | AD | Diabetic cardiomyopathy | 114/2092 | 203/8465 | 3.65e-22 | 3.06e-20 | 1.95e-20 | 114 |
| hsa054151 | Colorectum | AD | Diabetic cardiomyopathy | 114/2092 | 203/8465 | 3.65e-22 | 3.06e-20 | 1.95e-20 | 114 |
| hsa054152 | Colorectum | SER | Diabetic cardiomyopathy | 103/1580 | 203/8465 | 1.45e-25 | 1.61e-23 | 1.17e-23 | 103 |
| hsa054153 | Colorectum | SER | Diabetic cardiomyopathy | 103/1580 | 203/8465 | 1.45e-25 | 1.61e-23 | 1.17e-23 | 103 |
| hsa054154 | Colorectum | MSS | Diabetic cardiomyopathy | 106/1875 | 203/8465 | 2.47e-21 | 1.62e-19 | 9.92e-20 | 106 |
| hsa04210 | Colorectum | MSS | Apoptosis | 44/1875 | 136/8465 | 3.66e-03 | 1.66e-02 | 1.01e-02 | 44 |
| hsa054155 | Colorectum | MSS | Diabetic cardiomyopathy | 106/1875 | 203/8465 | 2.47e-21 | 1.62e-19 | 9.92e-20 | 106 |
| hsa042101 | Colorectum | MSS | Apoptosis | 44/1875 | 136/8465 | 3.66e-03 | 1.66e-02 | 1.01e-02 | 44 |
| Page: 1 2 3 4 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| PARP1 | BAS | Lung | Healthy | TM4SF1,KRT19,C3, etc. | 1.00e-01 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PARP1 | SNV | Missense_Mutation | rs79529505 | c.1223N>G | p.Val408Gly | p.V408G | P09874 | protein_coding | deleterious(0) | benign(0.367) | TCGA-A2-A0CQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| PARP1 | SNV | Missense_Mutation | rs79529505 | c.1223N>G | p.Val408Gly | p.V408G | P09874 | protein_coding | deleterious(0) | benign(0.367) | TCGA-A2-A0YJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
| PARP1 | SNV | Missense_Mutation | rs377195931 | c.919N>A | p.Asp307Asn | p.D307N | P09874 | protein_coding | tolerated(0.23) | benign(0.189) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| PARP1 | SNV | Missense_Mutation | rs377195931 | c.919G>A | p.Asp307Asn | p.D307N | P09874 | protein_coding | tolerated(0.23) | benign(0.189) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
| PARP1 | SNV | Missense_Mutation | rs79529505 | c.1223N>G | p.Val408Gly | p.V408G | P09874 | protein_coding | deleterious(0) | benign(0.367) | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| PARP1 | SNV | Missense_Mutation | c.2032N>C | p.Asp678His | p.D678H | P09874 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR | |
| PARP1 | SNV | Missense_Mutation | c.2524G>A | p.Glu842Lys | p.E842K | P09874 | protein_coding | tolerated(0.18) | benign(0.026) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| PARP1 | SNV | Missense_Mutation | novel | c.2971G>C | p.Val991Leu | p.V991L | P09874 | protein_coding | deleterious(0.01) | possibly_damaging(0.796) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PARP1 | SNV | Missense_Mutation | novel | c.1102A>C | p.Thr368Pro | p.T368P | P09874 | protein_coding | tolerated(0.29) | benign(0.079) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PARP1 | SNV | Missense_Mutation | c.268N>A | p.Glu90Lys | p.E90K | P09874 | protein_coding | tolerated(0.09) | possibly_damaging(0.566) | TCGA-B6-A0IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | Quinazolinedione derivative 2 | |||
| 142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | inhibitor | 223366069 | RUCAPARIB | |
| 142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | inhibitor | CHEMBL1094636 | NIRAPARIB | |
| 142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | 4-Carboxamido-isoindolinone derivative 2 | |||
| 142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | CC-486 | |||
| 142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 5 | |||
| 142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | OLAPARIB | OLAPARIB | 28454547,25144364,26650448 | |
| 142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | 4-Carboxamido-isoindolinone derivative 3 | |||
| 142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | Phthalazine ketone derivative 3 | |||
| 142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | RUCAPARIB | RUCAPARIB |
| Page: 1 2 3 4 5 6 7 8 9 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |